TL;DR: Supplementing 5-aminolevulinate (5-ALA) during liver ischemia mitigates reperfusion injury by reprogramming macrophage polarization toward an anti-inflammatory M2 state. This metabolic shift, mediated by the downregulation of the CX3CR1 receptor, triggers the secretion of CHIL3/CHI3L1, a protein that hepatocytes internalize to restore lipid metabolism and mitochondrial function.
Abstract: Liver resection and transplantation surgeries are accompanied by hepatic ischemia-reperfusion (HIR) injury that hampers the subsequent liver recovery. Given that the liver is the main organ for metabolism and detoxification, ischemia-reperfusion in essence bestows metabolic stress upon the liver and disrupts local metabolic and immune homeostasis. Most of the recent and current research works concerning HIR have been focusing on addressing HIR-induced hepatic injury and inflammation, instead of dealing with the metabolic reprogramming and restoration of redox homeostasis. As our previous work uncovers the importance of 5-aminolevulinate (5-ALA) synthesis during stress adaptation, here we evaluate the effects of supplementing 5-ALA to mitigate HIR injury. Our results reveal that supplementing 5-ALA promotes macrophagic M2 polarization via downregulation of RelA and CX3CR1 in mice following HIR, while M2 macrophage-produced CHIL3/CHI3L1 also manifests beneficial effects to the recovery of hepatic metabolism. 5-ALA and CHIL3/CHI3L1 together mitigate HIR-induced mitochondrial dysfunction and hepatocellular injuries, which may be developed into safe and effective clinical treatments to attenuate HIR injuries.
Introduction: The Metabolic Challenge of HIR
Hepatic ischemia-reperfusion (HIR) injury is an unavoidable consequence of liver resection and transplantation. When blood flow is stopped (ischemia) and then restored (reperfusion), the liver experiences a massive surge in reactive oxygen species (ROS) and a collapse of metabolic homeostasis. While most research focuses on dampening the resulting inflammatory "firestorm," this paper investigates the metabolic reprogramming required for the liver to recover. The authors look to nature for inspiration—specifically hibernating mammals, which naturally upregulate 5-ALA to survive extreme metabolic stress. They aim to determine if exogenous 5-ALA can act as a metabolic "rescue" signal to prevent the cascade of cell death and dysfunction following HIR.
Methodology
The researchers employed a multi-scale approach combining in vivo mouse models and in vitro human and mouse cell cultures:
- HIR Mouse Model: A 70% liver ischemia model was used, with 5-ALA administered via intraperitoneal injection during the ischemic phase.
- Genetic and Cellular Models: Cx3cr1 knockout (KO) mice were used to investigate the role of this specific chemokine receptor. Primary mouse hepatocytes, macrophages, and the human L-02 hepatocyte line were subjected to oxygen-glucose deprivation and reoxygenation (OGD/R) to mimic HIR.
- Metabolic Profiling: Seahorse assays measured ATP production, metabolic cages tracked whole-animal energy expenditure, and RNA-seq mapped global gene expression changes (OMIX002840, OMIX002841, OMIX002843).
- Clinical Validation: Paired pre- and post-transplantation liver samples and serum from 20 patients were used to validate the clinical relevance of 5-ALA and CHI3L1 pathways.
Metabolic Reprogramming and Macrophage Cross-talk
The study reveals that the 5-ALA pathway is highly fragile during HIR. The injury naturally suppresses key enzymes in the 5-ALA synthesis pathway, such as ALAD and UROS, leading to a deficiency of downstream metabolites right when the liver needs them most.
A sophisticated "help signal" mechanism was identified: 5-ALA suppresses the RelA-CX3CR1 axis in macrophages, shifting them from a pro-inflammatory (M1) to a pro-healing (M2) state. These M2 macrophages then secrete CHIL3 (CHI3L1 in humans). In a surprising twist, hepatocytes internalize the secreted CHIL3 protein, which then acts directly on mitochondria to boost lipid catabolism and ATP production without increasing oxidative stress.
Key Results
- Reduced Liver Damage: 5-ALA treatment (30 mg/kg) significantly lowered serum AST, ALT, and LDH levels and reduced the number of apoptotic cells in the liver.
- Metabolic Restoration: 5-ALA promoted lipid catabolism post-reperfusion, preventing the accumulation of toxic lipid droplets. Quantitative data shows a significant drop in porphobilinogen (PBG) levels during ischemia and reperfusion, which 5-ALA supplementation aims to counteract.
- Synergistic Protection: While 5-ALA or CHIL3 alone provide some benefit, a combined treatment significantly enhances the recovery of hepatic lipid metabolism and reduces injury markers more effectively than either alone.
Limitations and Future Work
Future work is needed to optimize the therapeutic window and determine if multiple doses are beneficial. Additionally, since 5-ALA is a heme precursor, high doses could theoretically trigger porphyria, requiring careful clinical screening. While the paper shows hepatocytes take up CHIL3, the specific receptor or endocytic pathway responsible for this internalization remains to be fully characterized. Finally, long-term effects on liver regeneration and fibrosis need further investigation beyond the initial 24-hour window.
Summary updated